Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway

Lu,Rujian; Zhou,Qian; Ju,Linling; Chen,Lin; Wang,Feng; Shao,Jianguo

doi:10.3892/or.2021.8123

Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway

Authors:
- Rujian Lu
- Qian Zhou
- Linling Ju
- Lin Chen
- Feng Wang
- Jianguo Shao
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Nantong Third People's Hospital, Nantong University, Nantong, Jiangsu 226006, P.R. China, Department of Internal Medicine, Medical School of Nantong University, Nantong, Jiangsu 226006, P.R. China, Nantong Institute of Liver Disease, Nantong Third People's Hospital, Nantong University, Nantong, Jiangsu 226006, P.R. China, Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226006, P.R. China
Published online on: June 28, 2021 https://doi.org/10.3892/or.2021.8123
Article Number: 172
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common malignant tumor type and it is associated with poor prognosis. The identification of potential biomarkers is of great significance for the early diagnosis and treatment of lung cancer. Non‑small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The present study aimed to investigate the mechanism via which thyroid hormone receptor‑interacting protein 13 (TRIP13) participates in the malignant progression of NSCLC. Immunohistochemistry, reverse transcription‑quantitative PCR and western blotting were used to assess the expression level of TRIP13. According to The Cancer Genome Atlas database, TRIP13 was upregulated in NSCLC tissues compared with adjacent normal tissues. Moreover, TRIP13 knockdown increased apoptosis, induced cell cycle arrest in the S phase and inhibited the proliferation, invasion and migration of H1299 cells in vitro. Furthermore, TRIP13 upregulation was closely associated with tumor metastasis via epithelial‑mesenchymal transformation. In conclusion, TRIP13 could promote the malignant progression of lung cancer, and TRIP13 may be a potential biomarker for the early diagnosis and treatment of NSCLC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2012. View Article : Google Scholar : PubMed/NCBI
2	Bade B and Dela Cruz C: Lung cancer 2020: Epidemiology, etiology, and prevention. Clin Chest Med. 41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
3	Schuller HM: The impact of smoking and the influence of other factors on lung cancer. Expert Rev Respir Med. 13:761–769. 2019. View Article : Google Scholar : PubMed/NCBI
4	Rivera GA and Wakelee H: Lung cancer in never smokers. Adv Exp Med Biol. 893:43–57. 2016. View Article : Google Scholar : PubMed/NCBI
5	Jones GS and Baldwin DR: Recent advances in the management of lung cancer. Clin Med (Lond). 18 (Suppl 2):S41–S46. 2018. View Article : Google Scholar : PubMed/NCBI
6	Steven A, Fisher SA and Robinson BW: Immunotherapy for lung cancer. Respirology. 21:821–833. 2016. View Article : Google Scholar : PubMed/NCBI
7	Kim D, Lee YS, Kim DH and Bae SC: Lung cancer staging and associated genetic and epigenetic events. Mol Cells. 43:1–9. 2020.PubMed/NCBI
8	Skřičková J, Kadlec B, Venclíček O and Merta Z: Lung cancer. Cas Lek Cesk. 157:226–236. 2018.
9	Wang Y, Huang J, Li B, Xue H, Tricot G, Hu L, Xu Z, Sun X, Chang S, Gao L, et al: A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 80:536–548. 2020. View Article : Google Scholar : PubMed/NCBI
10	Ye Q, Rosenberg S, Moeller A, Speir J, Su T and Corbett K: TRIP13 is a protein-remodeling AAA+ ATPase that catalyzes MAD2 conformation switching. Elife. 4:e073672015. View Article : Google Scholar : PubMed/NCBI
11	Clairmont CS, Sarangi P, Ponnienselvan K, Galli LD, Csete I, Moreau L, Adelmant G, Chowdhury D, Marto JA and D'Andrea AD: TRIP13 regulates DNA repair pathway choice through REV7 conformational change. Nat Cell Biol. 22:87–96. 2020. View Article : Google Scholar : PubMed/NCBI
12	Yost S, de Wolf B, Hanks S, Zachariou A, Marcozzi C, Clarke M, de Voer R, Etemad B, Uijttewaal E, Ramsay E, et al: Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. Nat Genet. 49:1148–1151. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ma HT and Poon RYC: TRIP13 regulates both the activation and inactivation of the spindle-assembly checkpoint. Cell Rep. 14:1086–1099. 2016. View Article : Google Scholar : PubMed/NCBI
14	Tao Y, Yang G, Yang H, Song D, Hu L, Xie B, Wang H, Gao L, Gao M, Xu H, et al: TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget. 8:26718–26731. 2017. View Article : Google Scholar : PubMed/NCBI
15	Yao J, Zhang X, Li J, Zhao D, Gao B, Zhou H, Gao S and Zhang L: Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-β1/smad3. Cancer Cell Int. 18:2082018. View Article : Google Scholar : PubMed/NCBI
16	Ju L, Li X, Shao J, Lu R, Wang Y and Bian Z: Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma. Oncol Rep. 40:3794–3802. 2018.PubMed/NCBI
17	Sheng N, Yan L, Wu K, You W, Gong J, Hu L, Tan G, Chen H and Wang Z: TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Cell Death Dis. 9:4022018. View Article : Google Scholar : PubMed/NCBI
18	Gao Y, Liu S, Guo Q, Zhang S, Zhao Y, Wang H, Li T, Gong Y, Wang Y, Zhang T, et al: Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway. Int J Biol Sci. 15:1488–1499. 2019. View Article : Google Scholar : PubMed/NCBI
19	Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y, Zhang T, Zhou J and Wang P: TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol. 121:200–206. 2019. View Article : Google Scholar : PubMed/NCBI
20	Zhang Q, Dong Y, Hao S, Tong Y, Luo Q and Aerxiding P: The oncogenic role of TRIP13 in regulating proliferation, invasion, and cell cycle checkpoint in NSCLC cells. Int J Clin Exp Pathol. 12:3357–3366. 2019.PubMed/NCBI
21	Mittal V: Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Pastushenko I and Blanpain C: EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
24	Yeung KT and Yang J: Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
25	Saitoh M: Involvement of partial EMT in cancer progression. J Biochem. 164:257–264. 2018. View Article : Google Scholar : PubMed/NCBI
26	Zhang G, Zhu Q, Fu G, Hou J, Hu X, Cao J, Peng W, Wang X, Chen F and Cui H: TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. Br J Cancer. 121:1069–1078. 2019. View Article : Google Scholar : PubMed/NCBI
27	Zhu MX, Wei CY, Zhang PF, Gao DM, Chen J, Zhao Y, Dong SS and Liu BB: Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. J Exp Clin Cancer Res. 38:4092019. View Article : Google Scholar : PubMed/NCBI
28	Alfieri C, Chang L, Zhang Z, Yang J, Maslen S, Skehel M and Barford D: Molecular basis of APC/C regulation by the spindle assembly checkpoint. Nature. 536:431–436. 2016. View Article : Google Scholar : PubMed/NCBI
29	Alfieri C, Chang L and Barford D: Mechanism for remodelling of the cell cycle checkpoint protein MAD2 by the ATPase TRIP13. Nature. 559:274–278. 2018. View Article : Google Scholar : PubMed/NCBI
30	Ye Q, Kim D, Dereli I, Rosenberg SC, Hagemann G, Herzog F, Tóth A, Cleveland DW and Corbett KD: The AAA+ ATPase TRIP13 remodels HORMA domains through N-terminal engagement and unfolding. EMBO J. 36:2419–2434. 2017. View Article : Google Scholar : PubMed/NCBI
31	Lu S, Qian J, Guo M, Gu C and Yang Y: Insights into a crucial role of TRIP13 in human cancer. Comput Struct Biotechnol J. 17:854–861. 2019. View Article : Google Scholar : PubMed/NCBI
32	Lu S, Guo M, Fan Z, Chen Y, Shi X, Gu C and Yang Y: Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer. Am J Transl Res. 11:4397–4410. 2019.PubMed/NCBI
33	Lu W and Kang Y: Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 49:361–374. 2019. View Article : Google Scholar : PubMed/NCBI
34	Venhuizen J, Jacobs F, Span P and Zegers M: P120 and E-cadherin: Double-edged swords in tumor metastasis. Semin Cancer Biol. 60:107–120. 2020. View Article : Google Scholar : PubMed/NCBI
35	Strouhalova K, Přechová M, Gandalovičová A, Brábek J, Gregor M and Rosel D: Vimentin intermediate filaments as potential target for cancer treatment. Cancers (Basel). 12:1842020. View Article : Google Scholar : PubMed/NCBI
36	Xie Q, Zhu Z, He Y, Zhang Z, Zhang Y, Wang Y, Luo J, Peng T, Cheng F, Gao J, et al: A lactate-induced Snail/STAT3 pathway drives GPR81 expression in lung cancer cells. Biochim Biophys Acta Mol Basis Dis. 1866:1655762020. View Article : Google Scholar : PubMed/NCBI
37	Agarwal S, Behring M, Kim HG, Chandrashekar DS, Chakravarthi BVSK, Gupta N, Bajpai P, Elkholy A, Al Diffalha S, Datta PK, et al: TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. Mol Oncol. 14:3007–3029. 2020. View Article : Google Scholar : PubMed/NCBI
38	Kurita K, Maeda M, Mansour MA, Kokuryo T, Uehara K, Yokoyama Y, Nagino M, Hamaguchi M and Senga T: TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion. Oncol Lett. 12:5240–5246. 2016. View Article : Google Scholar : PubMed/NCBI